about
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination.USP26 regulates TGF-β signaling by deubiquitinating and stabilizing SMAD7Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnoverCyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.A giant novel gene undergoing extensive alternative splicing is severed by a Cornelia de Lange-associated translocation breakpoint at 3q26.3.Protein phosphatase 2A regulatory subunits and cancer.Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinomaThe roles of ubiquitin modifying enzymes in neoplastic disease.HER2 signatures in breast cancer: ready to go to print?Deciphering the roles of lncRNAs in breast development and disease.Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.Platforms for Investigating LncRNA Functionsc-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progressionAuthor Correction: c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progressionStructural and Functional Characterization of Ubiquitin Variant Inhibitors of USP15Ubiquitination and adaptive responses to BRAF inhibitors in MelanomaUSP26 regulates TGF-β signaling by deubiquitinating and stabilizing SMAD7Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in MelanomaMELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma
P50
Q27851451-B3296633-0D73-419E-9629-577C6EA89068Q30666768-F0F45327-2B7E-44DF-AD67-074A8CD23AB2Q33625848-B8087904-0EB5-4E7C-9E4F-98966077FDAFQ34535458-4E878183-85B2-4E54-A22D-A1814DD57448Q34621219-F36179D3-6A40-4EC1-9D3B-00439315B81FQ36973564-0CE16719-9AF0-4ED1-A31D-D56F61223287Q37202956-DE63F6EE-C891-47D7-BC17-E2B70C241FD0Q38843100-41E07984-2EDD-4D02-AA45-CAFEAB2D4B3FQ47783548-0694D2FB-598D-406F-92EF-FBAE9DC4D52EQ54686576-D3EBECDE-104A-4E96-8282-2A5112334727Q54975879-31223031-51C7-40D2-AED0-961283C3B476Q54976764-84D9C177-92CA-4C65-A548-6B6B26D8D34BQ64326917-9E634167-434F-4ED6-B9D1-41EC381030C4Q90287704-99B55FD2-7EB3-422B-818C-02DB31AF0B60Q91198438-E0535A3B-142C-4F47-86FF-2F8CA3A2A2B7Q91322122-5F157170-CDB0-48B9-8E16-A8CB9D4177E4Q91835001-1F96FA00-FF20-4526-8633-79346EA78376Q92472751-C3F12DE8-0D85-41E0-B8FA-3A1014DF6E8BQ92642778-CB7B0BBC-EDF0-499E-B046-E8EA3FAB37AAQ92755767-75AFFF71-56E1-4598-A1D0-D46DC065C2D4
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pieter J Eichhorn
@ast
Pieter J Eichhorn
@en
Pieter J Eichhorn
@es
Pieter J Eichhorn
@nl
type
label
Pieter J Eichhorn
@ast
Pieter J Eichhorn
@en
Pieter J Eichhorn
@es
Pieter J Eichhorn
@nl
prefLabel
Pieter J Eichhorn
@ast
Pieter J Eichhorn
@en
Pieter J Eichhorn
@es
Pieter J Eichhorn
@nl
P108
P106
P1153
7004166602
P21
P31
P496
0000-0001-5840-943X